During the last session, NLS Pharmaceutics AG (NASDAQ:NLSP)’s traded shares were 0.28 million. At the end of the trading day, the stock’s price was $0.40, reflecting an intraday loss of 0.98% or $0.0. The 52-week high for the NLSP share is $3.10, that puts it down -675.0 from that peak though still a striking 17.5% gain since the share price plummeted to a 52-week low of $0.33. The company’s market capitalization is $7.28M, and the average intraday trading volume over the past 10 days was 0.57 million shares, and the average trade volume was 252.87K shares over the past three months.
NLS Pharmaceutics AG (NLSP) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. NLSP has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.
NLS Pharmaceutics AG (NASDAQ:NLSP) trade information
NLS Pharmaceutics AG (NLSP) registered a 0.98% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.98% in intraday trading to $0.40 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 8.76%, and it has moved by -30.66% in 30 days. Based on these gigs, the overall price performance for the year is -84.29%. The short interest in NLS Pharmaceutics AG (NASDAQ:NLSP) is 0.1 million shares and it means that shorts have 1.7 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.75, which implies an increase of 96.86% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12.00 and $13.50 respectively. As a result, NLSP is trading at a discount of -3275.0% off the target high and -2900.0% off the low.
NLS Pharmaceutics AG (NLSP) estimates and forecasts
Statistics show that NLS Pharmaceutics AG has outperformed its competitors in share price, compared to the industry in which it operates. NLS Pharmaceutics AG (NLSP) shares have gone down -51.90% during the last six months, with a year-to-date growth rate more than the industry average at 42.00% against 11.10.
While earnings are projected to return -313.20% in 2022.
NLS Pharmaceutics AG is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
NLS Pharmaceutics AG (NASDAQ:NLSP)’s Major holders
NLS Pharmaceutics AG insiders own 28.99% of total outstanding shares while institutional holders control 8.84%, with the float percentage being 12.45%. Citadel Advisors Llc is the largest shareholder of the company, while 6 institutions own stock in it. As of Mar 30, 2022, the company held over 21632.0 shares (or 0.11% of all shares), a total value of $30501.0 in shares.
The next largest institutional holding, with 21700.0 shares, is of Renaissance Technologies, LLC’s that is approximately 0.11% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $30597.0.
Data provided on May 30, 2022 indicates that Fidelity NASDAQ Composite Index Fund owns about 14362.0 shares. This amounts to just over 0.07 percent of the company’s overall shares, with a $9766.0 market value.